Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has given ...